Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021
HomeEXECUTIVESDr. Nick Poulios Appointed Chief Executive Officer at Brain Health Therapeutics

Dr. Nick Poulios Appointed Chief Executive Officer at Brain Health Therapeutics

Brain Health Therapeutics, Inc., is a company developing novel patented technologies to improve outcomes for neurological disorder patients.  Today they announced  the appointment of Dr. Nick Poulios as Chief Executive Officer of the company.

The company reports that Dr. Poulios is a business executive, editor, author, and market access expert. He brings to Brain Health Therapeutics more than two decades of executive leadership and international experience in biotechnology, pharmaceutical, diagnostics and global health, as well as a global network of relationships within the pharma/diagnostics community and industry that will enhance the company’s ability to pursue partnerships and financings.

In addition, Dr. Poulios was VP of Market Access, Strategic Pricing & Reimbursement for Elan Pharmaceuticals in charge of Tysabri for MS (Multiple Sclerosis), Bapineuzumab (Alzheimer’s) and Prialt (Chronic Pain). Most recently, Dr. Poulios was Head of Medical Outcomes Reimbursement & Economics at Roche Molecular Diagnostics. He has had similar positions at Roche Pharma, Baxter Bioscience and Gen-Prob Molecular Diagnostics.

Brain Health Therapeutics has partnered with a major US university which through NIH funded Research has uncovered a technology that combines two FDA approved drugs that are shown to be effective in altering disease progression in Alzheimer’s and other neurodegenerative diseases such as MS and Parkinson’s.

The new CEO of the company, Dr. Poulios reports, “Combining these two drugs through our patented formulation eliminates the side effects of the first drug which vastly reduce its use, while retaining its remarkably beneficial effects produced by slowing amyloid protein plaque growth believed to be the cause of the disease.”

A preclinical study published in the Journal of Alzheimer’s Disease found that very small doses of tetrahydrocannabinol (THC), can slow the production of beta- amyloid proteins, thought to be a key contributor to the progression of Alzheimer’s. The problem is that long term use of THC can produce side effects, such as adverse physical, mental, emotional, and cognitive changes.

“We are moving rapidly to begin pre-clinical development of our proprietary therapy,” said Dr. Benjamin Hoehn, MD, PhD who recently joined Brain Health Therapeutics as Chief Medical Officer. Most recently, Dr. Hoehn, was the CMO for J&J’s Codman Neuro Franchise and continues to make vast contributions to the rapidly expanding fields of neuroscience, neurosurgery, and healthcare.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy